Immunovant (IMVT) has reported positive initial Phase 2 results for Batoclimab in Graves’ disease. The data show a more than 50% response rate in patients, defined as the normalization of T3 and T4 hormone levels without increasing the dose of anti-thyroid medication. Additionally, the 680mg dosage resulted in an 87% reduction in IgG levels, with safety and tolerability aligned with prior data. The Phase 2 data validates the anti-FcRn approach for Graves' disease, with approximately 45 patients involved in the study.
$IMVT Ph 2 data (batoclimab FcRN) in Graves' disease 50% response rate & 81% IgG reduction 🔘N=~45 🔘680mg 87% IgG reduction 🔘Anti-TSHR autoantibody levels suppressed 🔘Safety/tolerability aligned with prior data 🔘POC data validates anti-FcRn approach 🔘Graves' (~116k annual…
$SLS (+11.5% pre) SELLAS Life Sciences (SLS) Granted FDA Orphan Drug Designation for SLS009 - SI https://t.co/zZAFSXlHVy
$IMVT (+10.4% pre) Immunovant (IMVT) Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease - SI https://t.co/DDpFkN7bUw
$GRCL (+4.5% pre) Gracell Bio (GRCL) Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus - SI https://t.co/sf4GYoHdHc
BOFA $IMVT 1401 achieved meaningfully greater than 50% disease normalization, and patients tapered anti-thyroid medication. •Data appear good, but with limitations (uncontrolled study; few details); edge up POS to 50%, PTnow $51.
$IMVT REPORTS POSITIVE INITIAL PHASE 2 RESULTS FOR BATOCLIMAB IN GRAVES’ DISEASE 1.Efficacy: •Response Rate: More than 50% response rate in patients. This response is defined as the normalization of T3 and T4 hormone levels without increasing the dose of anti-thyroid…